Chihiro Fujii
Overview
Explore the profile of Chihiro Fujii including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
115
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nishigori R, Hamatani M, Yoshitomi H, Kimura K, Takata M, Ashida S, et al.
Brain
. 2025 Mar;
PMID: 40042820
Neuromyelitis optica (NMO) is an acute inflammatory demyelinating disease of the CNS. The presence of astrocyte-targeted AQP4-immunoglobulin G (IgG) in peripheral blood is a major factor in its diagnosis. Previous...
2.
Fujii C, Hiraishi M, Yamashita K, Tsunamoto H, Fujimoto W, Odajima S, et al.
Circ Rep
. 2024 Oct;
6(10):448-455.
PMID: 39391547
Background: A novel cardioprotective drug, vericiguat, reduces the risk of cardiovascular mortality for patients already on guideline-directed medical therapy. However, the effect of vericiguat on left ventricular (LV) reverse remodeling...
3.
Niino M, Isobe N, Araki M, Ohashi T, Okamoto T, Ogino M, et al.
Mult Scler Relat Disord
. 2024 Aug;
90:105829.
PMID: 39182455
Background: The previous Japanese clinical practice guidelines for multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD) were published in 2017. Recently, for the first time in 6 years, the...
4.
Nakajima A, Yanagimura F, Saji E, Shimizu H, Toyoshima Y, Yanagawa K, et al.
Acta Neuropathol
. 2024 Apr;
147(1):76.
PMID: 38658413
Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune disease of the CNS characterized by the production of disease-specific autoantibodies against aquaporin-4 (AQP4) water channels. Animal model studies suggest that anti-AQP4...
5.
Nishiura N, Kubo S, Fujii C, Shima Y, Ikuta A, Osakada K, et al.
Circ J
. 2024 Jan;
88(6):938-943.
PMID: 38267035
Background: Clinical outcomes after percutaneous coronary intervention have improved with the use of drug-eluting stents, but data beyond 10 years are limited. The purpose of this study was to evaluate...
6.
Kimura K, Nishigori R, Hamatani M, Sawamura M, Ashida S, Fujii C, et al.
Neurol Neuroimmunol Neuroinflamm
. 2023 Nov;
11(1).
PMID: 37949669
Background And Objectives: Resident memory T (Trm) cells are a unique population that can survive and function in a compartmentalized tissue with inflammatory potential. We aim to investigate the alteration...
7.
Fujita R, Aratake Y, Nakata K, Fujii C, Kondo T
Intern Med
. 2023 Apr;
62(22):3317-3320.
PMID: 37032080
Objective The interleukin-6 (IL-6) inhibitor satralizumab is an established treatment for neuromyelitis optica spectrum disorder (NMOSD). Although IL-6 inhibitors are generally well-tolerated, serious infections, including sepsis, can occur. In this...
8.
Ashida S, Kondo T, Fujii C, Hamatani M, Mizuno T, Ochi H
Front Neurol
. 2022 Oct;
13:1012857.
PMID: 36203996
Objective: Multiple sclerosis (MS) is an immune-mediated demyelinating disease of the central nervous system. Without reliable diagnostic biomarkers, the clinical and radiological heterogeneity of MS makes diagnosis difficult. Although magnetic...
9.
Hamatani M, Ochi H, Kimura K, Ashida S, Hashi Y, Okada Y, et al.
Mol Neurobiol
. 2022 Jun;
59(9):5276-5283.
PMID: 35689766
Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system (CNS). Its early phase is characterized by a relapse-remitting disease course, followed by disability progression in...
10.
Uzura Y, Takeuchi H, Ashida S, Fujii C, Shishido-Hara Y, Inaba T, et al.
J Neuroimmunol
. 2022 Feb;
365:577823.
PMID: 35158108
We present the case of a 52-year-old woman with right hemiparesis due to a mass lesion in the left parietal white matter and corpus callosum. The lesion was hyperintense on...